Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (1)
  • CDK
    (1)
  • Calcium Channel
    (1)
  • GSK-3
    (1)
  • HIV Protease
    (1)
  • Hydroxylase
    (1)
  • P2X Receptor
    (2)
  • PDE
    (1)
  • Transferase
    (2)
  • Others
    (10)
Filter
Search Result
Results for "

ro 3

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    20
    TargetMol | Activity
  • Natural Products
    1
    TargetMol | inventory
  • Isotope Products
    2
    TargetMol | natural
RO-3
T55131026582-88-6
RO3 is a selective antagonist of homomeric P2X3 and heteromeric P2X2/3 receptor
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Ro 3-7410
T3436061470-08-4
Ro 3-7410 is an active hydroxy metabolite of bufuralol.
  • Inquiry Price
Size
QTY
Ro 3-5940 HCl
T3435917469-40-8
Ro 3-5940 HCl is a psychoactive agent, increasing in production of serotonin in central nervous system tissue.
  • $1,520
6-8 weeks
Size
QTY
Zalcitabine
T01107481-89-2
Zalcitabine (Dideoxycytidine)(Dideoxycytidine;ddC; 2', 3'-Dideoxycytidine) is a nucleoside analog reverse transcriptase inhibitor (NRTI); At low concentrations, It can potently inhibit HIV replication by binding to reverse transcriptase terminated synthesis of viral DNA chain.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Bufuralol
T3061154340-62-4
Bufuralol is a Adrenergic Agent.
  • $1,530
8-10 weeks
Size
QTY
Ro 20-1724
T1970629925-17-5
Ro 20-1724 (4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone) is a widely used inhibitor of cyclic nucleotide phosphodiesterase with IC50 of 2.0 μM and Ki of 3.1 μM.
  • $37
In Stock
Size
QTY
Mefloquine
T0860L53230-10-7
Mefloquine (Ro 215998), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus, and cancer research.
  • $148
In Stock
Size
QTY
TargetMol | Inhibitor Sale
R547
T6312741713-40-6In house
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1 2 4 with Ki of 2 nM 3 nM 1 nM. It is less potent to CDK7 and GSK3α β, while inactive to other kinases. Phase 1.
  • $45
In Stock
Size
QTY
Ro 31-8220 Mesylate
T6643138489-18-6
Ro 31-8220 Mesylate (Bisindolylmaleimide IX mesylate) is a pan-PKC inhibitor for PKC-α/βI/βII/γ/ε (IC50: 5/24/14/27/24 nM), and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β.
  • $44
In Stock
Size
QTY
TargetMol | Citations Cited
AF-353
T2087865305-30-2
AF-353 (Ro-4), an effective and orally bioavailable antagonist of the P2X3/P2X2/3 receptor, inhibits human and rat P2X3 (pIC50= 8.0).
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
RO-5328673
T710001310817-94-7
RO-5328673 is a dual NK2/NK3 antagonist. O5328673. [(3)H]RO5328673 bound to a single saturable site on hNK2, hNK3 and gpNK3 with high-affinity. RO5328673 acted as an insurmountable antagonist at both human and guinea-pig NK3 receptors in the [(3)H]IP accumulation assay. In binding kinetic analyses, [(3)H]RO5328673 had fast association and dissociation rates at hNK2 while it had a fast association rate and a remarkably slow dissociation rate at gp and hNK3. In electrophysiological recordings of gp SNpc, RO5328673 inhibited the senktide-induced potentiation of spontaneous activity of dopaminergic neurons with an insurmountable mechanism of action. RO5328673 exhibited in-vivo activity in gerbils, robustly reversing the senktide-induced locomotor activity.
  • $2,120
8-10 weeks
Size
QTY
Bufuralol (hydrochloride)
T2168460398-91-6
Bufuralol hydrochloride (Ro 3-4787 hydrochloride) is a potent non-selective, orally active β-adrenoreceptor antagonist with partial agonist activity, which is also a CYP2D6 probe substrate [1] [2].
  • $198
35 days
Size
QTY
Ro-23-9424
T28598115622-58-7
Ro-23-9424 is a dual-action cephalosporin with a fleroxacin esterified at the 3' position and aminothiazolylmethoxyimino-type side chain at the 7 position. Ro-23-9424 has broad and potent antibacterial activity in vitro and in vivo.
  • $1,520
Backorder
Size
QTY
3-O-Methyltolcapone D7
T10118
3-O-Methyltolcapone D7 (Ro 40-7591 D7) is a deuterium labeled 3-O-Methyltolcapone. 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone which is a potent COMT inhibitor. Tolcapone crosses the blood-brain barrier and can be used for treatment of P
  • Inquiry Price
Size
QTY
PSI-6206 13C,d3
T125711256490-42-2
PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is a potent and selective HCV NS5B polymerase inhibitor.
  • $347
7-10 days
Size
QTY
Ro 31-8220
T6643L125314-64-9
Ro 31-8220 is a potent inhibitor of PKC with IC50 values of 5, 24, 14, 27, 24, and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε, and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1, and GSK3β with IC50 values of 3, 8, 15, and 38 nM, respectively, without affecting MKK3, MKK4, MKK6, and MKK7.
  • $1,520
1-2 weeks
Size
QTY
Ro 61-8048
T1896199666-03-0
Ro 61-8048 is a potent and selective inhibitor of kynurenine hydroxylase with an IC50 value of 37 nM.
  • $33
In Stock
Size
QTY
3-O-Methyltolcapone
T10119134612-80-9
3-O-Methyltolcapone (Ro 40-7591), a metabolite of Tolcapone, is a potent COMT inhibitor that crosses the blood-brain barrier and can be used for the treatment of Parkinson's disease.
  • Inquiry Price
Size
QTY
Ginsenoside Ro
T391534367-04-9
Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.
  • $64
In Stock
Size
QTY
Sibrafiban
T28775172927-65-0
Sibrafiban (RO 48-3657), an orally active, nonpeptide double-prodrug of Ro 44-3888, is a selective glycoprotein IIb IIIa receptor antagonist that inhibits platelet aggregation [1] [2] [3].
  • $977
6-8 weeks
Size
QTY